EMERGENT BIOSOLUTIONS INC. Lease, Cost
EMERGENT BIOSOLUTIONS INC. (EBS) reported Lease, Cost of $600.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. lease, cost for the quarter ending 2026-06-30 was $600.00K, a 14.29% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. lease, cost for the quarter ending 2026-03-31 was $800.00K, a 0.00% change year-over-year.
- EMERGENT BIOSOLUTIONS INC. lease, cost for the quarter ending 2025-12-31 was $1.20M, a 33.33% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. lease, cost for the quarter ending 2025-09-30 was $600.00K, a 33.33% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. lease, cost for fiscal 2025 was $3.30M, a 17.50% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. lease, cost for fiscal 2024 was $4.00M, a 16.67% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. lease, cost for fiscal 2023 was $4.80M, a 28.36% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. lease, cost for fiscal 2022 was $6.70M, a 2.90% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | $2.60M derived: sum of 3 quarters · filed 2026-08-06 | $3.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-01 | $2.00M derived: sum of 2 quarters · filed 2026-05-01 | $2.60M derived: sum of 3 quarters · filed 2026-05-01 | $3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.80M derived: sum of 2 quarters · filed 2026-02-27 | $2.50M derived: sum of 3 quarters · filed 2026-08-06 | $3.30M 10-K · filed 2026-02-27 |
| 2025-09-30 | $600.00K 10-Q · filed 2025-10-30 | $1.30M derived: sum of 2 quarters · filed 2026-08-06 | $2.10M 10-Q · filed 2025-10-30 | $3.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $700.00K 10-Q · filed 2026-08-06 | $1.50M 10-Q · filed 2026-08-06 | $2.40M derived: sum of 3 quarters · filed 2026-08-06 | $3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $800.00K 10-Q · filed 2026-05-01 | $1.70M derived: sum of 2 quarters · filed 2026-05-01 | $2.60M derived: sum of 3 quarters · filed 2026-05-01 | $3.70M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.80M derived: sum of 2 quarters · filed 2026-02-27 | $2.90M derived: sum of 3 quarters · filed 2026-02-27 | $4.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $900.00K 10-Q · filed 2025-10-30 | $2.00M derived: sum of 2 quarters · filed 2025-10-30 | $3.10M 10-Q · filed 2025-10-30 | $4.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.10M 10-Q · filed 2025-08-07 | $2.20M 10-Q · filed 2025-08-07 | $3.30M derived: sum of 3 quarters · filed 2026-02-27 | $4.60M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $1.10M 10-Q · filed 2025-05-08 | $2.20M derived: sum of 2 quarters · filed 2026-02-27 | $3.50M derived: sum of 3 quarters · filed 2026-02-27 | $4.60M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.40M derived: sum of 2 quarters · filed 2026-02-27 | $3.50M derived: sum of 3 quarters · filed 2026-02-27 | $4.80M 10-K · filed 2026-02-27 |
| 2023-09-30 | $1.30M 10-Q · filed 2024-11-07 | $2.40M derived: sum of 2 quarters · filed 2024-11-07 | $3.70M 10-Q · filed 2024-11-07 | $5.40M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $1.10M 10-Q · filed 2024-08-07 | $2.40M 10-Q · filed 2024-08-07 | $4.10M derived: sum of 3 quarters · filed 2025-03-04 | $5.80M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-02 | $3.00M derived: sum of 2 quarters · filed 2025-03-04 | $4.70M derived: sum of 3 quarters · filed 2025-03-04 | $6.40M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.40M derived: sum of 2 quarters · filed 2025-03-04 | $5.10M derived: sum of 3 quarters · filed 2025-03-04 | $6.70M 10-K · filed 2025-03-04 |
| 2022-09-30 | $1.70M 10-Q · filed 2023-12-11 | $3.40M derived: sum of 2 quarters · filed 2023-12-11 | $5.00M 10-Q · filed 2023-12-11 | $6.80M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-09 | $3.40M 10-Q · filed 2023-08-09 | $5.10M derived: sum of 3 quarters · filed 2024-03-08 | $6.80M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $1.70M 10-Q · filed 2023-05-10 | $3.40M derived: sum of 2 quarters · filed 2024-03-08 | $5.10M derived: sum of 3 quarters · filed 2024-03-08 | $6.90M derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $3.40M derived: sum of 2 quarters · filed 2024-03-08 | $5.20M derived: sum of 3 quarters · filed 2024-03-08 | $6.90M 10-K · filed 2024-03-08 |
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-09 | $3.50M derived: sum of 2 quarters · filed 2022-11-09 | $5.20M 10-Q · filed 2022-11-09 | $6.80M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-06-30 | $1.80M 10-Q · filed 2022-08-02 | $3.50M 10-Q · filed 2022-08-02 | $5.10M derived: sum of 3 quarters · filed 2023-12-11 | $6.40M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-03-31 | $1.70M 10-Q · filed 2022-04-29 | $3.30M derived: sum of 2 quarters · filed 2023-12-11 | $4.60M derived: sum of 3 quarters · filed 2023-12-11 | $5.90M derived: sum of 4 quarters · filed 2023-12-11 |
| 2020-12-31 | $1.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $2.90M derived: sum of 2 quarters · filed 2023-12-11 | $4.20M derived: sum of 3 quarters · filed 2023-12-11 | $5.60M 10-K/A · filed 2023-12-11 |
| 2020-09-30 | $1.30M 10-Q · filed 2021-11-05 | $2.60M derived: sum of 2 quarters · filed 2021-11-05 | $4.00M 10-Q · filed 2021-11-05 | $4.80M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $1.30M 10-Q · filed 2021-07-30 | $2.70M 10-Q · filed 2021-07-30 | $3.50M derived: sum of 3 quarters · filed 2022-02-25 | $4.40M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $1.40M 10-Q · filed 2021-04-30 | $2.20M derived: sum of 2 quarters · filed 2022-02-25 | $3.10M derived: sum of 3 quarters · filed 2022-02-25 | $4.00M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.70M derived: sum of 2 quarters · filed 2022-02-25 | $2.60M derived: sum of 3 quarters · filed 2022-02-25 | $3.30M 10-K · filed 2022-02-25 |
| 2019-09-30 | $900.00K 10-Q · filed 2020-11-06 | $1.80M derived: sum of 2 quarters · filed 2020-11-06 | $2.50M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $900.00K 10-Q · filed 2020-07-31 | $1.60M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $700.00K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |